Post a Free Blog

Submit A Press Release

At CWEB, we are always looking to expand our network of strategic investors and partners. If you're interested in exploring investment opportunities or discussing potential partnerships and serious inquiries. Contact: jacque@cweb.com

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
Anime
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Dark Comedy
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Music
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Thriller
Truck Series (TRUCK)
True Crime
Ultimate Fighting Championship (UFC)
US
Valorant
Western
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessUnderstanding SCYNEXIS's Financial Efficiency in the Biotech Industry

Understanding SCYNEXIS’s Financial Efficiency in the Biotech Industry

Add to Favorite
Added to Favorite


SCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company focused on developing innovative therapies for difficult-to-treat and life-threatening infections. The company is known for its antifungal treatments, particularly for conditions that are resistant to existing medications. In the competitive landscape, SCYNEXIS faces peers like Cidara Therapeutics, Bellerophon Therapeutics, each with their own focus areas and financial metrics.
In evaluating SCYNEXIS’s financial efficiency, the Return on Invested Capital (ROIC) is a critical metric. SCYX has a ROIC of -60.19%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 9.98%. This results in a ROIC to WACC ratio of -6.03, indicating that the company is not currently generating returns that cover its cost of capital.
Comparatively, Cidara Therapeutics (CDTX) also shows a negative ROIC of -72.84% against a WACC of 7.71%, leading to a ROIC to WACC ratio of -9.45. This suggests that Cidara, like SCYNEXIS, is struggling to generate sufficient returns on its invested capital relative to its cost.
Bellerophon Therapeutics (BLPH) has a ROIC of -728.98% and a WACC of 33.39%, leading to a ROIC to WACC ratio of -21.84. This indicates a significant gap between the returns generated and the cost of capital, highlighting inefficiencies in capital utilization.

Subscribe to get Latest News Updates

Latest News

You may like more
more